VCP Scanner
Stock Screener
Filter stocks with fundamental & technical criteria
Technical Scanner
RSI, Moving averages & volume momentum signals
Market Themes
Curated industry baskets & thematic leaders
Earnings Hub
Calendar, EPS surprise stats & earnings transcripts
Market News
Real-time market intelligence & AI overviews
Insider Buying
SEC Form 4 corporate insider purchases
Minervini — VCPContraction bases in Stage 2 uptrends
Minervini — Trend TemplateFull 8-rule Stage 2 screen
O'Neil — Cup with HandleBase breakouts with RS leadership
O'Neil — CANSLIM LeadersGrowth leaders with RS ≥ 85
Qullamaggie — High Tight FlagsPower plays after a large advance
Qullamaggie — Momentum Leaders1/3/6-month strength leaders
Livermore — Pivotal PointsMulti-touch resistance breakouts
View All Playbooks...
Breakouts
FAANG & Tech
AAPL vs MSFTNVDA vs AMDGOOGL vs META
Cloud & Cyber
CRM vs NOWCRWD vs PANWSNOW vs DDOG
Consumer & Auto
TSLA vs FAMZN vs WMTNFLX vs DIS
Finance & Crypto
JPM vs BACV vs MACOIN vs MSTR
Index & ETFs
SPY vs QQQVTI vs VOOSPY vs IWM
Compare Any Stocks...
DCF ValuationCalculate intrinsic value of US stocks
Market ValuationBuffett indicator, CAPE & macro gauges
Total ReturnSee dividends + price return history
DCA CalculatorSimulate recurring buys & compounding
VisualizeInteractive multi-year financial charts
Watchlist
Breakouts
WatchlistPricing
Ctrl K
Pricing
LEGN
← Back to Screener
VCP ScannerFree US Stock Screener & Financial Analysis

Find stocks. Analyze deeply. Research with clarity.

Data updated daily

Product

  • Screener
  • Themes
  • Valuation
  • Total Return
  • DCA Calculator
  • Pricing
  • News
  • Earnings

Resources

  • Market Valuation
  • Compare
  • Insider Activity
  • Methodology
  • How It Works
  • Glossary
  • Learn

Get Ideas

Get weekly market insights — free

© 2026 VCP Scanner
AboutPrivacyTermsRefund Policy
Not financial advice. Do your own research.
ScreenerBreakoutsCompareWatchlist
LEGNLegend Biotech Corporation
$18.57$3.4B
Overview & Tools
OverviewChart Terminal ↗Visualize
Valuation & Forecasts
Valuation ModelsEstimatesDCF Model
Price & Analyst Data
Analyst TargetsPrice History
Financial Statements
Income StatementBalance SheetCash FlowRatios & Margins
Performance
P/E HistoryRevenue HistoryEarnings HistoryDividend HistoryTotal Return
Discovery & Screens
Live BreakoutsStock ScreenerOwnership
HomeStocksLEGNEarnings History

LEGN logoLegend Biotech Corporation (LEGN) Earnings History

Net Loss

9 years of earnings data (2017–2025) · Currently unprofitable on a TTM basis

TTM Net Income
-$92M
● Net Loss
TTM EPS (Diluted)
$-0.47
Per share, diluted
YoY EPS Growth
-64.9%
Declining
Net Margin
-28.8%
After-tax profitability
EPS Growth Rate (CAGR)
1YN/A
3YN/A
5YN/A
10YN/A
Operating Margin-13.3%
Gross Margin60.3%
Return on Equity-29.1%
Return on Assets-17.4%
Record Annual Net Income$9MFY2017
Record Quarterly EPS$0.18Q2 2026
Consecutive Profitable Years0years
Q2 2026
Net Income$33M
EPS (Diluted)$0.18
YoY Growth-64.9%Declining
QoQ Growth+161.1%Excellent

Loading earnings history...

Legend Biotech Corporation (LEGN) Earnings Overview

As of October 3, 2026, Legend Biotech Corporation (LEGN) reported trailing twelve-month net income of -$92M, reflecting -64.9% year-over-year growth. The company earned $-0.47 per diluted share over the past four quarters, with a net profit margin of -28.8%.

Looking at the long-term picture, LEGN's historical earnings data spans multiple years. The company achieved its highest annual net income of $9M in fiscal 2017.

Legend Biotech Corporation is currently reporting a net loss, though operating performance should be evaluated in the context of growth investments and industry dynamics View revenue history →

Compared to peers including FATE (-$126M net income, -2051.1% margin), CRSP (-$451M net income, -16569.8% margin), BEAM (-$85M net income, -57.2% margin), LEGN has outperformed on profitability metrics. Compare LEGN vs FATE →

LEGN Earnings vs Peers

Earnings metrics vs comparable public companies

CompanyTTM Net IncomeTTM EPSNet MarginROEYoY GrowthCompare
LEGN logoLEGNCurrent
-$92M$-0.47-28.8%-29.1%-64.9%—
FATE logoFATE
-$126M$-1.05-2051.1%-51.8%+29.9%
CRSP logoCRSP
-$451M$-4.67-16569.8%-30.2%-49.1%
BEAM logoBEAM
-$85M$-0.82-57.2%-8.1%+82.3%
NTLA logoNTLA
-$400M$-3.00-609.9%-53.5%+27.4%
EDIT logoEDIT
-$74M$-0.62-395.0%-198.1%+37.5%
Best in group
Lowest in group

LEGN Historical Earnings Data (2017–2025)

9 years
Fiscal Year Net Income YoY % Operating Income EPS (Diluted) Net Margin Op. Margin
2025-$297M-67.7%-$137M$-1.60-28.8%-13.3%
2024-$177M+65.8%-$303M$-0.97-28.2%-48.3%
2023-$518M-16.1%-$439M$-2.94-181.8%-154.1%
2022-$446M-10.6%-$456M$-2.81-381.5%-389.4%
2021-$404M-51.5%-$392M$-2.74-586.4%-570.0%
2020-$266M-162.2%$0$-2.57-355.2%0.0%
2019-$102M-3549.1%-$133M$-1.01-164.4%-214.4%
2018-$3M-129.7%-$2M$-0.03-5.7%-3.1%
2017$9M-$14M$0.0739.7%58.4%

Download Data

Export LEGN earnings history in CSV or JSON format

Free sign-in required to download data

Consensus & Technical Research Suite
Open LEGN Terminal

LEGN Chart Terminal

WASM

Live VCP patterns, Cup & Handle overlays, support/resistance, and AI trade plans.

Launch Terminal

Live Breakouts Feed

LIVE

High-probability breakout stocks crossing their pivot across 5 pattern engines.

Explore Setups

Intrinsic Valuation

DCF models, multiple analysis, and analyst estimates.

Check Valuation

Historical Returns

9+ years return with dividends reinvested.

Calculate

Peer Comparison

Compare growth, multiples, and margins vs sector.

Compare

LEGN — Frequently Asked Questions

Quick answers to the most common questions about buying LEGN stock.

What is LEGN earnings per share (EPS)?

LEGN trailing twelve-month (TTM) diluted EPS is $-0.47, reflecting -64.9% year-over-year growth. The 5-year EPS CAGR is N/A. Complete EPS history from 2017 to 2025 is available in the table on this page.

What is Legend Biotech Corporation's net income?

Legend Biotech Corporation (LEGN) trailing twelve-month net income is $-92M as of 2025. Earnings declined -64.9% year-over-year.

Is LEGN profitable?

LEGN is not currently profitable on a TTM basis, reporting a net loss of $-92M. Net margin is -28.8%. Investors should monitor for a return to profitability.

What is LEGN's earnings growth rate?

LEGN compound annual EPS growth rates (CAGR): 1-Year: N/A, 3-Year: N/A, 5-Year: N/A, 10-Year: N/A. These figures measure the annualised rate of diluted EPS growth over each period, based on data from 2017 to 2025.

What are LEGN's profit margins?

Legend Biotech Corporation net profit margin is -28.8%, operating margin is -13.3%, and gross margin is +60.3%. Below-average margins reflect competitive or cost pressures. Return on Equity is -29.1%.

Is LEGN growing earnings?

LEGN earnings are declining — EPS fell -64.9% year-over-year. TTM net income dropped to $-92M. This contrasts with the 5-year CAGR of N/A.

What was LEGN's best earnings year?

Legend Biotech Corporation's highest annual net income on record is $9M, achieved in fiscal year 2017. Earnings history on this page spans 2017 to 2025 and includes all annual and quarterly figures.

What were LEGN's earnings last quarter?

LEGN's most recent reported quarter was Q2 2026. Net income was $33M with diluted EPS of $0.18. For a full breakdown of all quarters, see the quarterly earnings table on this page.

LEGN Earnings Over Time (2017–2025)

Net income & EPS — annual and quarterly view